Fig. 3: Relationships between change in gamma power and change in MADRS for KET 0.5 and MID. | Neuropsychopharmacology

Fig. 3: Relationships between change in gamma power and change in MADRS for KET 0.5 and MID.

From: Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial

Fig. 3

Ketamine demonstrated a moderate relationship between gamma reactivity at 30 min and change in MADRS score at 7 days post infusion. This relationship was less prevalent at the earlier time points and was non-existent for patients in the midazolam condition. More positive MADRS change scores (x-axes) indicates smaller decreases/an increase in MADRS from baseline. Correlation results are summarized in Supplementary Table 5.

Back to article page